000			nab a22 7a 4500
999			_c16591 _d16591
003			PC16591
005			20211005131122.0
008			210826b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_92616 _aLópez Muñoz, Francisco _eInstituto de Investigación i+12
245	0	0	_aRisk-benefit analysis of antidepressant drug treatment in the elderly. _h[revisión]
260			_bPsychogeriatrics : the official journal of the Japanese Psychogeriatric Society, _c2014
300			_a14(4):261-8.
500			_aFormato Vancouver: Alamo C, López Muñoz F, García García P, García Ramos S. Risk-benefit analysis of antidepressant drug treatment in the elderly. Psychogeriatrics. 2014 Dec;14(4):261-8.
501			_aPMID: 25495088
504			_aContiene 83 referencias
520			_aDepression in the elderly is a significant health issue that has the potential to seriously affect physical and emotional well-being. Therefore, the treatment of geriatric depression is necessary. Antidepressant treatment in older depressed patients is efficacious, but differences in the effectiveness of different classes of antidepressants have not been demonstrated. However, differences in tolerability profile are most recognizable in the elderly. With ageing, a series of changes occur in the elderly that modify both the pharmacokinetics and pharmacodynamics of antidepressants and may influence the efficacy, tolerability and safety of treatment in the elderly. Comorbidities require the use of other drugs, which increases the possibility of drug-drug interactions. Given these aspects, individualized therapy for each elderly patient is needed to achieve acceptable risk-benefit ratio. Effective treatment of depression in the elderly, which may require combined pharmacological with psychosocial treatment, can decrease both morbidity and mortality; it also may lead to reduced demands on family members and on health-care and social services.
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16591.pdf _ySolicitar documento
942			_2ddc _cREV _n0